Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/Icos Cialis Outpaces Bayer/GSK Levitra With 18% Share Of New Scripts

This article was originally published in The Pink Sheet Daily

Executive Summary

Cialis has tracked ahead of Levitra for “three weeks running,” Lilly reports. Both agents are in a head-to-head battle to overtake the market leader, Pfizer’s Viagra.

You may also be interested in...



Levitra Market Share Hurt By Lack of Branded Ads At Launch, GSK Says

GSK and Bayer were hesitant to launch Levitra with full product ads because of risk info, but the Cialis branded campaign revealed consumers were not dissuaded by product risks, GSK says. Sampling and internet sales of counterfeits have slowed growth in the category.

Levitra Market Share Hurt By Lack of Branded Ads At Launch, GSK Says

GSK and Bayer were hesitant to launch Levitra with full product ads because of risk info, but the Cialis branded campaign revealed consumers were not dissuaded by product risks, GSK says. Sampling and internet sales of counterfeits have slowed growth in the category.

Pfizer Viagra "Value Card" Offers Buy-Six-Get-One-Free Script Deal

The card program is available to patients who either pay out of pocket for Viagra or receive partial third-party coverage. Pfizer will dedicate full print and radio ads to the Value Card and update current TV commercials.

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel